Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

1. SARS-COV-2 VARIANTS' EFFECT ON PREGNANCY AND LONG-TERM OUTCOMES AMONG PREGNANT WOMEN AND THEIR NEWBORNS IN ESTONIA

   Tue, 04 Feb 2025 05:00:00 -0000

   Conditions: Pregnancy; COVID-19; Post-COVID / Long-COVID; Newborn Health; Miscarriages
   Interventions: Other: COVID-19 infection
   Sponsors: University of Tartu
   Completed

2. Venous Thromboembolism During COVID-19 Pandemic: Evaluation of the Association with the Vaccine and SARS-CoV-2 Infection

   Tue, 04 Feb 2025 05:00:00 -0000

   Conditions: Venous Thromboembolism
   Sponsors: IRCCS Azienda Ospedaliero-Universitaria di Bologna
   Completed

3. Impact of the Elevation Training Mask in CrossFit® Post-SARS-CoV-2 Infection.

   Mon, 03 Feb 2025 05:00:00 -0000

   Conditions: COVID19- Infection with SARS-CoV-2 Virus; SARS-CoV-2 Positive Patients; COVID-19 Pulmonary Complications; COVID Hematological Complications
   Interventions: Device: Elevation Training Mask; Device: Sham Elevation Training Mask
   Sponsors: University of Valladolid
   Completed

4. RegiStry Of the multiFaceted medIcal cenTer

   Tue, 04 Feb 2025 05:00:00 -0000

   Conditions: Chronic Non-communicable Diseases; Cardiovascular Diseases; COVID-19; Multimorbidity
   Sponsors: National Medical Research Center for Therapy and Preventive Medicine; State Healthcare Institution of the Tula Region Tula Regional Clinical Hospital
   Active, not recruiting

5. "Artificial Intelligence-Based Data Analysis Results and Mortality Prediction in Covid-19 Patients in Intensive Care"

   Tue, 28 Jan 2025 05:00:00 -0000

   Conditions: COVID-19
   Sponsors: Kocaeli City Hospital
   Active, not recruiting

6. Photobiomodulation Therapy Versus Integrated Myofascial Release Therapy Techniques in Patients with COVID19

   Tue, 28 Jan 2025 05:00:00 -0000

   Conditions: COVID 19 Disease
   Interventions: Radiation: Photobiomodulation; Procedure: Myofascial release therapy; Device: traditional chest physiotherapy
   Sponsors: Beni-Suef University
   Completed

7. Effect of Aerobic Training Versus Relaxation Techniques on Quality of Life in Patients With Post Covid-19 Irritable Bowel Syndrome

   Tue, 28 Jan 2025 05:00:00 -0000

   Conditions: Irritable Bowel Syndrome
   Interventions: Other: Aerobic training; Other: Relaxation techniques; Other: Low fodmap diet
   Sponsors: Cairo University
   Not yet recruiting

8. Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

   Fri, 24 Jan 2025 05:00:00 -0000

   Conditions: SARS CoV-2 Post-Acute Sequelae
   Interventions: Drug: Nirmatrelvir/ritonavir; Drug: Remdesivir
   Sponsors: Mount Sinai Hospital, Canada; Unity Health Toronto; Kingston Health Sciences Centre (Kingston); Niagara Health System
   Recruiting

9. Mindfulness-Based Stress Reduction Versus Lifestyle Intervention for Long-Haul Covid-19 Parosmia

   Thu, 23 Jan 2025 05:00:00 -0000

   Conditions: COVID-19
   Interventions: Behavioral: Mindfulness-Based Stress Reduction; Behavioral: Lifestyle Intervention
   Sponsors: Washington University School of Medicine
   Terminated

10. Persistent COVID-19 Symptoms in Minia

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: COVID - 19
    Sponsors: Fayoum University
    Completed

11. The Effect of Classical Music on Dental Students' Stress and Anxiety During the COVID-19 Pandemic

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: Psychological Factors
    Interventions: Other: Questionnaire; Other: listening to music
    Sponsors: Karabuk University; Ankara University
    Completed

12. A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: CVXGA (CVXGA50); Biological: COMIRNATY®
    Sponsors: CyanVac LLC; Biomedical Advanced Research and Development Authority
    Recruiting

13. Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: COVID-19; Influenza a; Influenza B
    Interventions: Diagnostic Test: COVID/Flu Detect™ Rapid Self-Test
    Sponsors: InBios International, Inc.
    Recruiting

14. A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infections
    Interventions: Drug: Treatment B; Drug: Treatment A
    Sponsors: Pfizer
    Completed

15. A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: Influenza,Human; COVID-19
    Interventions: Biological: Investigational Influenza Vaccine; Biological: COVID-19 Vaccine; Combination Product: Influenza and COVID Combination Vaccine; Biological: Licensed Influenza Vaccine 1; Biological: Licensed Influenza Vaccine 2; Other: Placebo
    Sponsors: BioNTech SE; Pfizer
    Active, not recruiting

16. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: COVID-19 SARS-CoV-2 Infection
    Interventions: Drug: ibuzatrelvir; Drug: placebo
    Sponsors: Pfizer
    Recruiting

17. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Thu, 23 Jan 2025 05:00:00 -0000

    Conditions: Coronavirus Disease (COVID-19)
    Interventions: Drug: Molnupiravir; Drug: Placebo
    Sponsors: Merck Sharp & Dohme LLC
    Recruiting

18. Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Device: Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
    Sponsors: ExThera Medical Corporation
    Not yet recruiting

19. Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: Long COVID; Sars-CoV-2 Infection; Coronavirus Infections; COVID-19
    Interventions: Drug: Baricitinib; Other: Placebo
    Sponsors: Wes Ely; National Institutes of Health (NIH); National Institute on Aging (NIA)
    Recruiting

20. The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: Pulmonary Complications; Cardiovascular Complications; Renal Complications; COVID-19
    Interventions: Other: Blood samples; Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Recruiting

21. A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: PF-07817883
    Sponsors: Pfizer
    Active, not recruiting

22. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: PASC Post Acute Sequelae of COVID-19
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Not yet recruiting

23. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Hepatic Impairment and in Healthy Subjects with Normal Hepatic Function

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: ALG-097558
    Sponsors: Aligos Therapeutics; National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

24. Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome
    Interventions: Biological: IgPro20; Biological: Placebo
    Sponsors: CSL Behring
    Recruiting

25. Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)

    Thu, 30 Jan 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Biological: SARS-CoV-2 omicron virus dose arm 1; Biological: SARS-CoV-2 omicron virus dose arm 2; Biological: SARS-CoV-2 omicron virus dose arm 3
    Sponsors: Hvivo
    Recruiting

26. Long COVID-19 Intervention (COVIDL/MIQoL)

    Thu, 23 Jan 2025 05:00:00 -0000

    Conditions: Long COVID-19
    Interventions: Behavioral: Multicomponent intervention
    Sponsors: Consorci Sanitari de Terrassa
    Active, not recruiting

27. A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

    Wed, 29 Jan 2025 05:00:00 -0000

    Conditions: Non-Small Cell Lung Cancer; Metastatic Melanoma; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Metastatic Pancreatic Cancer; Glioblastoma; Malignant Mesothelioma; COVID-19
    Interventions: Drug: Bemcentinib
    Sponsors: BerGenBio ASA
    Completed

28. RECOVER-ENERGIZE Platform Protocol

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Behavioral: Personalized Cardiopulmonary Rehabilitation; Behavioral: Structured Pacing; Other: Education; Other: Usual Care
    Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

29. COVID-19 Quick Start - Test and Treat in Africa

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: Duke University; Duke Clinical Research Institute; Clinton Health Access Initiative, Nigeria
    Active, not recruiting

30. Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: Long COVID; PASC Post Acute Sequelae of COVID 19
    Interventions: Drug: Valacyclovir celecoxib dose 1; Drug: Valacyclovir celecoxib dose 2; Drug: Placebo
    Sponsors: Bateman Horne Center
    Completed

31. RECOVER-AUTONOMIC Platform Protocol

    Thu, 23 Jan 2025 05:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Drug: IVIG + Coordinated Care; Drug: IVIG Placebo + Coordinated Care; Drug: Ivabradine + Coordinated Care; Drug: Ivabradine Placebo + Coordinated Care; Drug: IVIG + Usual Care; Drug: IVIG Placebo + Usual Care; Drug: Ivabradine + Usual Care; Drug: Ivabradine Placebo + Usual Care
    Sponsors: Kanecia Obie Zimmerman
    Recruiting

32. Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: SARS CoV 2 Infection
    Interventions: Biological: IMNN-101
    Sponsors: Imunon
    Active, not recruiting

33. Investigating the Effectiveness of Vimida

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: Long COVID; Post COVID-19 Condition
    Interventions: Behavioral: vimida
    Sponsors: Gaia AG; Medical School Hamburg; Institut Long-Covid Rostock
    Recruiting

34. Diet and Fasting for Long COVID

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: Long Covid19; Long COVID
    Interventions: Other: Low sugar diet and 10-12 hour eating window; Other: Low sugar diet, 8 hour eating window and fasting
    Sponsors: Pacific Northwest University of Health Sciences
    Completed

35. CX-4945 in Viral Community Acquired Pneumonia

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: Community-acquired Pneumonia; SARS-CoV-2 -Associated Pneumonia; Influenza With Pneumonia
    Interventions: Drug: CX-4945 (SARS-CoV-2 domain); Drug: Placebo (SARS-CoV-2 domain); Drug: CX-4945 (Influenza virus domain); Drug: Placebo (Influenza virus domain)
    Sponsors: Senhwa Biosciences, Inc.
    Recruiting

36. Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: Long COVID; Post Acute Sequelae of COVID-19; Post-Acute COVID-19
    Interventions: Drug: Ensitrelvir; Other: Placebo
    Sponsors: Timothy Henrich; Shionogi Inc.
    Active, not recruiting

37. Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial

    Thu, 30 Jan 2025 05:00:00 -0000

    Conditions: Post-Acute COVID-19; Post-Acute COVID-19 Syndrome; Post-Acute COVID-19 Infection; Long COVID; Long Covid19; Dyspnea; Orthostasis; Cognitive Impairment
    Interventions: Other: Comprehensive Rehabilitation; Other: Augmented Usual Care
    Sponsors: University of Pennsylvania; Medical College of Wisconsin; National Institutes of Health (NIH)
    Enrolling by invitation

38. "The Effect of Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19"

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Behavioral: Aerobic Exercise and Strength Training
    Sponsors: Pamukkale University
    Completed

39. Promoting Engagement and COVID-19 Testing for Health

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Behavioral: COVID-19 Test Reporting; Behavioral: Personalized Nudges via Text Messaging; Behavioral: Non-personalized Nudges via Text Messaging
    Sponsors: Emory University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Morehouse School of Medicine; Georgia Institute of Technology
    Active, not recruiting

40. Water-based Activity to Enhance Recovery in Long COVID-19

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Behavioral: WATER+CT; Behavioral: Usual Care
    Sponsors: VA Office of Research and Development
    Recruiting

41. Facemasks and Chronic Pain Patients With Hearing Loss

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: Hearing Loss; Chronic Pain
    Interventions: Behavioral: Verbal communication
    Sponsors: Salem Anaesthesia Pain Clinic
    Completed

42. Cell Therapy with Treg Cells Obtained from Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated with COVID-19 And/or Acute Respiratory Distress Syndrome (THYTECH2)

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Systemic Inflammatory Response Syndrome
    Interventions: Biological: Allogeneic thyTreg 5.000.000; Biological: Allogeneic thyTreg 10.000.000
    Sponsors: Hospital General Universitario Gregorio Marañon; Instituto de Salud Carlos III
    Recruiting

43. Study of Obeldesivir in Children and Adolescents With COVID-19

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Obeldesivir
    Sponsors: Gilead Sciences
    Terminated

44. COVID-19 Disease & Vaccine Survey in Africa

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: COVID-19; Vaccine Hesitancy
    Interventions: Behavioral: Questionnaire
    Sponsors: Salem Anaesthesia Pain Clinic
    Completed

45. COVID Infection in Pediatric Surgical Patient

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Diagnostic Test: Rapid antigen test
    Sponsors: Salem Anaesthesia Pain Clinic
    Recruiting

46. Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: SARS-CoV-2; COVID-19; Post-Acute COVID-19 Syndrome
    Interventions: Biological: Pfizer-BioNTech COVID-19 mRNA vaccine
    Sponsors: Pfizer
    Active, not recruiting

47. Fluvoxamine for Long COVID-19

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Drug: Fluvoxamine
    Sponsors: Washington University School of Medicine; Balvi COVID Fund; BJH Townley Fund
    Active, not recruiting

48. REVERSE-Long COVID-19 With Baricitinib Study

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome
    Interventions: Drug: Baricitinib 4 MG; Drug: Placebo
    Sponsors: Vanderbilt University Medical Center; Emory University; University of California, San Francisco; University of Minnesota; Vanderbilt University; Yale University
    Withdrawn

49. REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: Post-COVID-19 Syndrome; Fatigue Syndrome, Chronic
    Interventions: Other: Anhydrous Enol-Oxaloacetate, a "Medical Food"; Other: White Rice Flour
    Sponsors: Terra Biological LLC; Bateman Horne Center
    Completed

50. Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: abatacept infusion; Drug: Placebo group
    Sponsors: University of Minnesota
    Recruiting

51. A Study of Silmitasertib (CX-4945) in Healthy Subject

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: CX-4945
    Sponsors: Senhwa Biosciences, Inc.
    Completed

52. Research of the Long-COVID-19 Syndrome in the Children

    Thu, 23 Jan 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Genetic: Device
    Sponsors: Samara State Medical University
    Completed

53. Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: Post COVID-19 Condition (PCC)
    Interventions: Other: Digital intervention (DiLCoS); Other: Data collection
    Sponsors: University Hospital, Basel, Switzerland; State Secretariat for Education Research and Innovation, Switzerland; European Union's Horizon Europe research and innovation programme
    Recruiting

54. AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: AZD7442; Biological: Placebo; Biological: Remdesivir
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT); University of Copenhagen; Medical Research Council; Kirby Institute; Washington D.C. Veterans Affairs Medical Center; Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; National Heart, Lung, and Blood Institute (NHLBI); US Department of Veterans Affairs; Prevention and Early Treatment of Acute Lung Injury; Cardiothoracic Surgical Trials Network; AstraZeneca; University of Minnesota
    Completed

55. AT1001 for the Treatment of Long COVID

    Thu, 23 Jan 2025 05:00:00 -0000

    Conditions: Long COVID; Long COVID-19; Post Acute COVID-19 Syndrome; Post Acute Sequelae of COVID-19
    Interventions: Drug: Larazotide Acetate; Drug: Placebo
    Sponsors: Massachusetts General Hospital
    Recruiting

56. Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Dietary Supplement: Nicotinamide Riboside (NR); Behavioral: Mind-body reprocessing therapy (MBRT); Behavioral: Care as usual; Dietary Supplement: Placebo
    Sponsors: University Hospital, Akershus
    Active, not recruiting

57. Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Behavioral: COVID Prevention Program (CPP)
    Sponsors: San Diego State University; Family Health Centers of San Diego
    Active, not recruiting

58. Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Sponsors: AstraZeneca
    Completed

59. Cognitive Rehabilitation for Long COVID

    Thu, 23 Jan 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Behavioral: Cognitive Rehabilitation; Other: Education
    Sponsors: McMaster University; Canadian Institutes of Health Research (CIHR)
    Completed

60. Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: Post-COVID-19 Syndrome
    Interventions: Drug: Prednisolone 20 mg/ 5 mg; Drug: Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12); Drug: Placebo for Vitamin B compound; Drug: Placebo for Prednisolon
    Sponsors: Wuerzburg University Hospital; University Hospital Tuebingen; University Hospital Schleswig-Holstein
    Active, not recruiting

61. Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

    Wed, 29 Jan 2025 05:00:00 -0000

    Conditions: Viral Lung Infection and Acute Respiratory Failure
    Interventions: Drug: Tozorakimab; Drug: Placebo
    Sponsors: AstraZeneca
    Recruiting

62. Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Shionogi Protease Inhibitor (S-217622); Drug: placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

63. Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: Post COVID-19 Condition; Long COVID
    Interventions: Drug: Rintatolimod; Other: Placebo / Normal Saline
    Sponsors: AIM ImmunoTech Inc.; Amarex Clinical Research
    Completed

64. COVID-19 Testing and Vaccine Literacy for Women With Criminal Legal System Involvement

    Thu, 30 Jan 2025 05:00:00 -0000

    Conditions: COVID-19 Pandemic
    Interventions: Behavioral: Tri-City COVID Attitudes Study
    Sponsors: University of Kansas Medical Center; National Institute on Minority Health and Health Disparities (NIMHD)
    Completed

65. Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: Breastfeeding; COVID-19 Infection; COVID-19 Vaccine; Remdesivir; Antibiotics
    Interventions: Biological: COVID-19 Exposure; Drug: Antibiotic
    Sponsors: University of California, San Diego
    Recruiting

66. Addressing Post-COVID-19 Musculoskeletal Symptoms

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: Telemedicine; Musculoskeletal Disease; SARS-CoV-2; Pain; COVID-19; Exercise
    Interventions: Other: Multicomponent exercise program; Other: Tele-health primary care rehabilitation program
    Sponsors: Universidad Europea de Madrid
    Completed

67. RECLAIM: Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: Long COVID; Post COVID Condition; Post Acute Sequelae of COVID-19
    Interventions: Drug: Ibudilast; Drug: Pentoxifylline; Other: Placebo
    Sponsors: University Health Network, Toronto
    Suspended

68. Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Antihistamine; Drug: Amantadine
    Sponsors: Consorci Sanitari de Terrassa; Institut Català de la Salut
    Recruiting

69. Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Heart Disease
    Sponsors: National Human Genome Research Institute (NHGRI)
    Completed

70. Low-dose Naltrexone for Post-COVID Fatigue Syndrome

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Post-Viral Fatigue Syndrome
    Interventions: Drug: Low-Dose Naltrexone; Other: Placebo
    Sponsors: Luis Nacul; University of British Columbia; Canadian Institutes of Health Research (CIHR); Provincial Health Services Authority; Women's Health Research Institute of British Columbia
    Recruiting

71. COVID-19 Experiences in the SELF Cohort

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Environmental Health Sciences (NIEHS)
    Enrolling by invitation

72. Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Myocardial Injury; COVID-19; Vaccine Reaction
    Sponsors: University of Colorado, Denver; American Heart Association; National Institute of Allergy and Infectious Diseases (NIAID)
    Active, not recruiting

73. Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

    Thu, 30 Jan 2025 05:00:00 -0000

    Conditions: Systemic Inflammation; Neuroinflammation; Microvascular Thrombosis
    Interventions: Drug: IV normal saline; Drug: IV immunoglobulin
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Enrolling by invitation

74. COVID-19 Testing and Vaccination Among Spanish Speakers

    Wed, 29 Jan 2025 05:00:00 -0000

    Conditions: COVID-19; Vaccinations
    Interventions: Behavioral: NuestraSaludSegura
    Sponsors: Wake Forest University Health Sciences; National Institute on Minority Health and Health Disparities (NIMHD)
    Completed

75. COVID-19 Immunity and Changes Over Time

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: Chinese University of Hong Kong
    Withdrawn

76. Covid-19 Vaccine Immune Response in Multiple Sclerosis

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: Multiple Sclerosis
    Interventions: Other: Blood Test 1; Other: Blood Test 2
    Sponsors: University Hospitals of North Midlands NHS Trust
    Active, not recruiting

77. Exercise in Adults with Post-Acute Sequelae of SARS-CoV-2 (COVID-19) Infection Study

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: Exercise Prescription
    Sponsors: Baylor Research Institute; Sports Academy
    Completed

78. Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.

    Wed, 29 Jan 2025 05:00:00 -0000

    Conditions: COVID-19; Immunocompromised Host
    Sponsors: ANRS, Emerging Infectious Diseases
    Completed

79. Understanding the Long-term Impact of COVID on Children and Families

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Sponsors: NYU Langone Health; National Heart, Lung, and Blood Institute (NHLBI)
    Active, not recruiting

80. The Effect of Motivational Messages on Emergency Nurses

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: Satisfaction; Compassion Fatigue; Communication, Social
    Interventions: Other: Motivation
    Sponsors: Istanbul Saglik Bilimleri University
    Completed

81. A Study of Acute Respiratory Infections in Global Outpatient Setting

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Acute Respiratory Infection
    Interventions: Diagnostic Test: Nasal Swab Sample
    Sponsors: Janssen Research & Development, LLC
    Completed

82. Respiratory Virus Metagenomics After COVID-19

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: COVID-19 Respiratory Infection
    Sponsors: Chinese University of Hong Kong
    Recruiting

83. EU Secondary Data Post-Authorisation Safety Study of AZD1222

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: COVID-19, Vaccine Adverse Events of Special Interest
    Interventions: Biological: AZD1222
    Sponsors: AstraZeneca; RTI Health Solutions
    Completed

84. A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: COVID-19 Prevention
    Interventions: Biological: Ad26.COV2.S; Other: Placebo; Biological: Influenza Vaccine
    Sponsors: Janssen Vaccines & Prevention B.V.
    Completed

85. A Study of Baricitinib (LY3009104) in Children With COVID-19

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: Covid19; Corona Virus Infection
    Interventions: Drug: Baricitinib
    Sponsors: Eli Lilly and Company
    Recruiting

86. A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

    Mon, 27 Jan 2025 05:00:00 -0000

    Conditions: COVID-19, SARS-CoV-2
    Interventions: Biological: AZD1222
    Sponsors: AstraZeneca
    Terminated

87. COVID-19 Serology in People Living with HIV in Hong Kong

    Fri, 24 Jan 2025 05:00:00 -0000

    Conditions: HIV Infections; SARS-CoV-2 Infection; Vaccination; Infection
    Interventions: Other: blood sampling
    Sponsors: Chinese University of Hong Kong
    Completed

88. The Impact of COVID-19 on Pulmonary Procedures

    Tue, 28 Jan 2025 05:00:00 -0000

    Conditions: COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    Interventions: Other: Survey Administration
    Sponsors: M.D. Anderson Cancer Center
    Recruiting

89. A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: Coronavirus Disease-2019 (COVID-19) Prevention
    Interventions: Biological: Ad26.COV2.S
    Sponsors: Janssen Vaccines & Prevention B.V.
    Completed

90. COVID-19 Vaccinations With a Sweepstakes

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Behavioral: Philly Vax Sweepstakes
    Sponsors: University of Pennsylvania; Philadelphia Department of Public Health
    Completed

91. Novel Experimental COVID-19 Therapies Affecting Host Response

    Wed, 22 Jan 2025 05:00:00 -0000

    Conditions: COVID-19; SARS-CoV-2 Infection; Coronavirus Infection
    Interventions: Drug: TXA127; Drug: TRV027; Drug: Placebo; Drug: Fostamatinib
    Sponsors: Sean Collins; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
    Completed

92. Outpatient Treatment With Anti-Coronavirus Immunoglobulin

    Fri, 31 Jan 2025 05:00:00 -0000

    Conditions: COVID; SARS-CoV2 Infection; Covid19
    Interventions: Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Other: Placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
    Recruiting

93. A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

    Tue, 04 Feb 2025 05:00:00 -0000

    Conditions: COVID-19 Prevention
    Interventions: Biological: Ad26.COV2.S
    Sponsors: Janssen Vaccines & Prevention B.V.
    Completed

94. Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD)

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Diagnostic Test: COVID-19 RT-PCR test; Other: COVID-19 Vaccine Education Campaign
    Sponsors: University of Rochester; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Completed

95. Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused CBO

    Wed, 29 Jan 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Behavioral: Onsite Point-of-care
    Sponsors: Montefiore Medical Center; The Fortune Society; University of Bristol; National Institute on Minority Health and Health Disparities (NIMHD); Cepheid
    Active, not recruiting

96. Patient Experiences with the COVID-19 Vaccination After Breast Cancer Treatment

    Wed, 29 Jan 2025 05:00:00 -0000

    Conditions: Breast Cancer Related Lymphedema; Covid19
    Interventions: Other: Survey
    Sponsors: Massachusetts General Hospital
    Completed

97. Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

    Thu, 23 Jan 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Dietary Supplement: Vitamin D3
    Sponsors: University of Chicago; Rush University Medical Center
    Completed

98. Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations

    Thu, 30 Jan 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Other: Dissemination and Implementation Research
    Sponsors: University of Oklahoma; National Institutes of Health (NIH); National Institute of General Medical Sciences (NIGMS)
    Completed

99. COVID-19 Close Contact Self-Testing Study

    Mon, 03 Feb 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Behavioral: COVID-19 self-test; Behavioral: COVID-19 test referral
    Sponsors: University of Pennsylvania; Public Health Management Corporation
    Completed

100. Effects of Face Masks During Exercise

     Wed, 22 Jan 2025 05:00:00 -0000

     Conditions: Cardiopulmonary; Exercise; Cognitive Performance; Covid19
     Interventions: Other: Cardiopulmonary Exercise Test; Other: Cognitive Performance Test
     Sponsors: Baylor Research Institute
     Completed

101. Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.

     Fri, 24 Jan 2025 05:00:00 -0000

     Conditions: Covid19; Eye Diseases
     Interventions: Diagnostic Test: swabbing of conjunctiva
     Sponsors: Universitaire Ziekenhuizen KU Leuven
     Terminated

102. Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

     Fri, 31 Jan 2025 05:00:00 -0000

     Conditions: COVID-19
     Interventions: Biological: ChAdV68-S; Biological: ChAdV68-S-TCE; Biological: SAM-LNP-S; Biological: SAM-LNP-S-TCE; Other: Sodium Chloride, 0.9%
     Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Gritstone bio, Inc.
     Completed

103. Impact of COVID-19 on GU Disease

     Fri, 31 Jan 2025 05:00:00 -0000

     Conditions: COVID-19 Infection; Genitourinary Cancer; Benign Urologic Conditions
     Sponsors: Icahn School of Medicine at Mount Sinai
     Active, not recruiting

104. Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali

     Thu, 23 Jan 2025 05:00:00 -0000

     Conditions: Covid19
     Interventions: Diagnostic Test: SARS-CoV-2 screening by molecular biology; Diagnostic Test: Serological screening
     Sponsors: Institut National de la Santé Et de la Recherche Médicale, France
     Completed

105. Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation

     Fri, 31 Jan 2025 05:00:00 -0000

     Conditions: Colorectal Cancer Screening
     Interventions: Other: Semi-structured interviews-Patients; Other: Semi-structured interviews-Health system
     Sponsors: Indiana University; Patient-Centered Outcomes Research Institute
     Completed

106. Inhaled Heparin for Hospitalised COVID-19 Patients

     Mon, 03 Feb 2025 05:00:00 -0000

     Conditions: Covid19
     Interventions: Drug: Unfractionated heparin
     Sponsors: Australian National University; Helwan University; Clinica San Camilo, Argentina; Frederick Health; Coney Island Hospital, Brooklyn, NY; Galeno Desenvolvimento de Pesquisas Clínicas; Dr Cipto Mangunkusumo General Hospital; Dr. Moewardi General Hospital, Surakarta, Indonesia
     Completed

107. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
     Interventions: Biological: Ad26.COV2.S; Other: Placebo
     Sponsors: Janssen Vaccines & Prevention B.V.
     Completed

108. Feasibility and Effectiveness of Home-behavioral Program for Adolescents with Migraine

     Thu, 23 Jan 2025 05:00:00 -0000

     Conditions: Headaches Chronic
     Interventions: Behavioral: Mindfulness
     Sponsors: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
     Completed

109. Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans

     Thu, 23 Jan 2025 05:00:00 -0000

     Conditions: COVID-19
     Sponsors: National Institute on Aging (NIA)
     Active, not recruiting

110. Nebulised Heparin in Patients With Severe COVID-19

     Mon, 03 Feb 2025 05:00:00 -0000

     Conditions: Covid19; Respiratory Failure
     Interventions: Drug: Nebulised unfractionated heparin (UFH)
     Sponsors: Australian National University
     Active, not recruiting

111. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
     Interventions: Biological: Ad26.COV2.S; Other: Placebo
     Sponsors: Janssen Vaccines & Prevention B.V.
     Completed

112. DEFINE - Evaluating Therapies for COVID-19

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: COVID-19
     Interventions: Drug: Nafamostat Mesilate; Drug: TD139; Other: Standard care; Biological: Allogeneic SARS-CoV-2 VSTs
     Sponsors: University of Edinburgh; University of Oxford; Latus Therapeutics; Scottish National Blood Transfusion Service (SNBTS)
     Recruiting

113. Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19

     Wed, 22 Jan 2025 05:00:00 -0000

     Conditions: COVID-19 Disease
     Interventions: Other: Data collection from lumbar puncture; Other: Data collection from blood draw; Other: CNS magnetic resonance imaging (MRI) imaging; Other: Microscopy of defined brain regions on autopsy specimens
     Sponsors: University Hospital, Basel, Switzerland; Botnar Research Centre for Child Health
     Completed

114. Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

     Wed, 29 Jan 2025 05:00:00 -0000

     Conditions: Acute Respiratory Distress Syndrome; ARDS (Moderate or Severe); COVID-19 Pneumonia
     Interventions: Biological: Mesenchymal stromal cells; Other: Placebo
     Sponsors: Masonic Cancer Center, University of Minnesota
     Completed

115. At Home Monitoring for Patients With Covid19

     Fri, 24 Jan 2025 05:00:00 -0000

     Conditions: Coronavirus
     Interventions: Device: Covidfree@home
     Sponsors: University Health Network, Toronto; Sunnybrook Health Sciences Centre; University of Toronto
     Completed

116. Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

     Wed, 22 Jan 2025 05:00:00 -0000

     Conditions: COVID
     Interventions: Drug: mavrilimumab; Other: Placebo
     Sponsors: Kiniksa Pharmaceuticals International, plc; Kiniksa Pharmaceuticals, Ltd.
     Completed

117. Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique

     Wed, 22 Jan 2025 05:00:00 -0000

     Conditions: COVID-19
     Sponsors: Institute of Tropical Medicine, Belgium; European and Developing Countries Clinical Trials Partnership (EDCTP); Instituto Nacional de Saude, Mozambique; Institut de Recherche pour le Developpement; UMC Utrecht
     Completed

118. A Study of Ad26.COV2.S in Adults (COVID-19)

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: Covid-19 Prevention
     Interventions: Biological: Ad26.COV2.S; Biological: Placebo
     Sponsors: Janssen Vaccines & Prevention B.V.
     Completed

119. SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival

     Wed, 29 Jan 2025 05:00:00 -0000

     Conditions: Covid19; Hypoxic Respiratory Failure
     Interventions: Drug: Isoflurane Inhalant Product; Drug: Sevoflurane inhalant product
     Sponsors: Sunnybrook Health Sciences Centre
     Recruiting

120. A Longitudinal Study of COVID-19 Sequelae and Immunity

     Mon, 03 Feb 2025 05:00:00 -0000

     Conditions: COVID-19
     Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
     Active, not recruiting

121. Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency

     Thu, 23 Jan 2025 05:00:00 -0000

     Conditions: Migraine, Hemicrania
     Interventions: Drug: Symptomatic drugs; Drug: Bridge therapy; Behavioral: Mindfulness program
     Sponsors: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
     Completed

122. Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: Behcet Disease; COVID; FMF
     Interventions: Other: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
     Sponsors: Istanbul University
     Completed

123. Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

     Mon, 27 Jan 2025 05:00:00 -0000

     Conditions: Acute and Long Term Effects of COVID-19 on Systemic Inflammation; Acute and Long Term Effects of COVID-19 on Lung Function; Acute and Long Term Effects of COVID-19 on Cardiac Function; Acute and Long Term Effects of COVID-19 on Kidney Function; Acute and Long Term Effects of COVID-19 on Brain Function
     Sponsors: National Institutes of Health Clinical Center (CC)
     Completed

124. Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients with Chronic Migraine and Medication Overuse

     Thu, 23 Jan 2025 05:00:00 -0000

     Conditions: Migraine Headache
     Interventions: Behavioral: Mindfulness
     Sponsors: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
     Completed

125. NCI COVID-19 in Cancer Patients, NCCAPS Study

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
     Interventions: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
     Sponsors: National Cancer Institute (NCI)
     Active, not recruiting

126. Vitamin D and COVID-19 Management

     Thu, 23 Jan 2025 05:00:00 -0000

     Conditions: COVID-19
     Interventions: Dietary Supplement: Ddrops® products, 50,000 IU, Oral; Dietary Supplement: Vitamin D3
     Sponsors: University of Alberta
     Completed

127. Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19

     Thu, 30 Jan 2025 05:00:00 -0000

     Conditions: Covid-19; Critical Illness; Attitude of Health Personnel; Attitude to Health; Health Behavior; Health Care Utilization
     Interventions: Behavioral: Brief educational video
     Sponsors: University of California, Los Angeles
     Completed

128. Tocilizumab for Patients With Cancer and COVID-19 Disease

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Pneumonia; Pneumonitis; Severe Acute Respiratory Distress Syndrome; Symptomatic COVID-19 Infection Laboratory-Confirmed
     Interventions: Biological: Tocilizumab
     Sponsors: National Cancer Institute (NCI)
     Terminated

129. Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

     Wed, 22 Jan 2025 05:00:00 -0000

     Conditions: COVID19; Influenza Vaccination; ACE Inhibitors; ARB; Antihistamine Allergy; Amantadine
     Interventions: Drug: Antihistamine; Drug: Amantadine; Drug: ACEI; Drug: ARB; Other: Influenza vaccine and COVID
     Sponsors: Consorci Sanitari de Terrassa; Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina; Institut Català de la Salut
     Recruiting

130. Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care

     Thu, 30 Jan 2025 05:00:00 -0000

     Conditions: COVID-19
     Interventions: Drug: Therapeutic Anticoagulation
     Sponsors: Unity Health Toronto; University of Vermont Medical Center; University of Sao Paulo; Hôpital Charles Lemoyne; William Osler Health System; MOUNT SINAI HOSPITAL; Trillium Health Partners; St. Joseph's Health Centre Toronto; The Ottawa Hospital; Hopital du Sacre-Coeur de Montreal; Michael Garron Hospital; University of Alberta; Southlake Regional Health Centre; Maisonneuve-Rosemont Hospital; Queen Elizabeth II Health Sciences Centre; Foothills Medical Centre; Alberta Health services; Peter Lougheed Centre; Mater Misericordiae University Hospital; King Saud University Medical City; King Fahad Medical City; King Faisal Specialist Hospital; Versiti; Barnes-Jewish Hospital; Al Ain Hospital
     Completed

131. Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.

     Wed, 22 Jan 2025 05:00:00 -0000

     Conditions: Coronavirus
     Interventions: Diagnostic Test: Serology; Genetic: Sequencing
     Sponsors: Institut National de la Santé Et de la Recherche Médicale, France
     Terminated

132. COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor

     Tue, 28 Jan 2025 05:00:00 -0000

     Conditions: Coronavirus Infections
     Interventions: Other: Observational Study
     Sponsors: Università Vita-Salute San Raffaele
     Recruiting

133. Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

     Tue, 04 Feb 2025 05:00:00 -0000

     Conditions: Idiopathic Pulmonary Fibrosis; Primary Sclerosing Cholangitis; Covid19 Pneumonia
     Interventions: Drug: [18F]FP-R01-MG-F2
     Sponsors: Stanford University; Pliant Therapeutics, Inc.
     Completed

134. Viral Infections in Healthy and Immunocompromised Hosts

     Wed, 22 Jan 2025 05:00:00 -0000

     Conditions: Anogenital Herpes; COVID-19; Herpes Labialis
     Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
     Recruiting